The MBP fusion protein restores the activity of the first phosphatase domain of CD45  by Lorenzo, Hans K et al.
The MBP fusion protein restores the activity of the ¢rst phosphatase
domain of CD45
Hans K. Lorenzo
a
, Donna Farber
1;b
, Vale
è
rie Germain
b
, Oreste Acuto
b
, Pedro M. Alzari
a;
*
a
Unite
è
d'Immunologie Structurale, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France
b
Unite
è
d'Immunologie Moleculaire, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France
Received 14 April 1997; revised version received 28 May 1997
Abstract CD45 is a receptor-like protein tyrosine phosphatase
critically involved in the regulation of initial effector functions in
B- and T-cells. The protein comprises two phosphatase (PTP)
domains in its cytoplasmic region. However, whether each PTP
domain has enzyme activity by itself or whether both domains are
required to build up a functional enzyme is unclear. We have
studied different constructions of human CD45 comprising the
two PTP domains, both separately and as a single protein, fused
to maltose-binding protein (MBP). In apparent contrast with
previous studies, we show that the first PTP domain of CD45
(when fused to MBP) may be a viable phosphatase in the absence
of the second domain. Phosphatase activity resides in the
monomeric form of the protein and is lost after proteolytic
cleavage of the fusion partner, indicating that MBP specifically
activates the first PTP domain. Furthermore, changes in the
optimal pH for activity with respect to wild-type CD45 suggest
that protein^protein interactions involving residues in the
neighbourhood of the catalytic site mediate enzyme activation.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
The activation and regulation of reaction cascades in signal-
ling pathways leading to proliferation and di¡erentiation in
eukaryotic cells is related to the balance of tyrosine phospho-
rylation/dephosphorylation controlled by the action of tyro-
sine kinases and phosphatases (reviewed in [1,2]). Receptor-
like protein tyrosine phosphatases (RPTP) exhibit a modular
structure that includes one or two intracellular PTP domains,
each homologous to soluble forms of monomeric phospha-
tases, a single membrane-spanning segment and a variable
extracellular domain [3]. The PTP domain is organized as a
central eight-stranded L-sheet £anked on both sides by K-heli-
ces, as revealed by the crystal structures of the soluble phos-
phatases PTP1B and Yop51 [4,5]. At the center of the active
site, the highly conserved sequence motif (I/V)HCXA-
GXXR(S/T) contributes the essential nucleophilic cysteine
residue and other functional groups required for phos-
photyrosine binding and catalysis [6,7].
CD45, a prototypic receptor-like PTPase, is a 180^220 kDa
protein highly expressed in hematopoietic cells. CD45 plays a
critical role in the response of leukocytes to antigen, where it
is involved in the early stages of the signal transduction path-
ways [8] (for review [9^11]). The two intracellular PTP do-
mains of CD45 share about 40% of sequence identities with
each other [3], and both contain a cysteine residue (Cys
828
in
PTP-I; Cys
1144
in PTP-II) within the conserved sequence mo-
tif. However, several mutational studies have indicated that
Cys
828
(but not Cys
1144
) is critical for phosphatase activity
[12,13]. The substitution Cys
828
s Ser completely abrogated
the enzymatic activity in recombinant forms [12^14] and in
cells [15], but the replacement Cys
1144
s Ser in the second
PTP domain resulted in a phosphatase with in vitro and in
vivo properties similar to those of the wild-type enzyme
[13,15]. These results suggest that only the ¢rst PTP domain,
but not the second, behaves as an active phosphatase. In
agreement with these observations, recombinant CD45^do-
main II alone yielded an inactive protein [13], and several
RPTPs lack the conserved cysteine within the second PTP
domain [16,17]. Furthermore, in RPTPs such as LAR and
HPTPK, the ¢rst PTP domain alone displayed a phosphatase
activity similar to that of the whole protein [18,19].
However, the ¢rst PTP of CD45 domain was found to be
inactive when expressed independently [12,13], suggesting that
in CD45, unlike other RPTPs, domain II is required for the
activity of domain I. This hypothesis is further substantiated
by the ¢nding that a single point mutation in the second
domain or the deletion of the region linking the two PTP
domains totally abrogated the phosphatase activity of CD45
[20]. Contrasting these data, Tan et al. have shown in eukary-
otic cells that the second domain of CD45 together with the
C-terminal part of the ¢rst domain (without the catalytic cys-
teine) may also be a viable phosphatase [21]. Therefore, it is
not clear at present whether the separate PTP domains of
CD45 have phosphatase activity by themselves, or whether
the enzymatic activity in one or both domains requires speci¢c
interdomain interactions.
We have studied di¡erent constructions containing the two
phosphatase domains of CD45, both separately and as a sin-
gle protein, fused to the maltose-binding protein (MBP). We
found that the ¢rst PTP domain of CD45 when expressed as a
MBP fusion protein is an active phosphatase in the absence of
the second domain, and that the enzymatic activity is lost
after proteolytic cleavage of the fusion partner, suggesting
that speci¢c interactions with an external factor are required
to stabilize the active conformation.
2. Materials and methods
2.1. Materials
p-Nitrophenylphosphate (p-NPP), 2-L-mercaptoethanol (2-ME), di-
thiotreitol (DTT) and D-maltose were purchased from Sigma. Pefa-
bloc0 from Boehringer Mannheim. Factor Xa, antiserum anti-MBP
and amylose resin were from New England BioLabs. Bradford re-
agent from Bio-Rads, and material for SDS-polyacrylamide gel elec-
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trophoresis, gel ¢ltration and ion exchange chromatography from
Pharmacia.
2.2. MBP^CD45 fusion constructs
Three fusion constructs of human CD45 (PTP domain-I, PTP do-
main-II and PTP domain-I+II) were generated according to the boun-
daries proposed by Streuli et al. [22] (Fig. 1). Thus, MBP^PTP-I
includes amino acid residues 575^886 (K
575
IYDLTTQALVE
886
) of
human CD45, MBP^PTP-II includes residues 940^1202
(Q
940
EENKST TDVIAS
1202
), and MBP^PTP-I+II includes residues
575^1202 (K
575
IYDLT TDVIAS
1202
). The sequences were PCR ampli-
¢ed from an expression plasmid containing the entire human CD45
T200 coding sequence using the primers: 5P-GGAATTCAGATC-
TAAAATCTATGATCTACAT-3P and 5P-GGAATTCAGATCTTT-
ACTGATTGTATTCCACCAA-3P (PTP-I); 5P-CGGGATCCCAAG-
AAGAAAATAAAAGT-3P, and 5P-CGGGATCCTTAGCTGGCAA-
TGACGTCATA-3P (PTP-II) and 5P-GGAATTCAGATCTAAAAT-
CTATGATCTACAT-3P and 5P-GGAATTCAGATCTTTAGCTGG-
CAATGACGTCATA-3P (PTP-I+II).
Ampli¢ed PCR fragments were ligated to pPDXa [23] which had
been previously linearized with BamHI, treated with calf intestinal
phosphatase, and gel puri¢ed. pPDXa contains the coding sequence
for maltose binding protein (MBP) under the control of the maltose
promoter and is a derivative of pMALcRI (New England BioLabs,
Beverly, MA). All the plasmids were transformed into competent
malE
ÿ
PD28 cells according to established protocols [24].
2.3. Expression and puri¢cation of recombinant forms of human CD45
Cultures of PD28 cells, induction and isolation of fusion proteins
were performed at 30³C using protocols previously described [25].
Protein puri¢cation was achieved by a¤nity chromatography in amy-
lose resin as described by the furnisher, followed by ion exchange
chromatography using a MonoQ column (Pharmacia) equilibrated
in a bu¡er containing 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, and
2 mM DTT. The presence of di¡erent MBP^CD45 forms was evi-
denced by anti-MBP Western blot. Cleavage of puri¢ed fusion pro-
teins was carried out by overnight incubation at 4³C with Factor Xa
(1:100, w:w). The PTP domains were separated from MBP by anion
exchange chromatography as described above. Protein puri¢cation
was tested by SDS-PAGE and the respective concentrations measured
by Bradford colorimetric assay.
2.4. PTPase assays
Kinetics of Michaelis-Menten were studied using p-NPP (10 mM
¢nal) as substrate in 50 mM imidazol (pH 7.0), 150 mM NaCl, 1 mM
EDTA, and 0.1% 2-ME (total volume of 50 Wl) at 37³C. The reaction
was allowed to proceed for 5^20 min and quenched with 500 Wl of 1 M
NaOH. The amount of dephosphorylated substrate was calculated
from the absorbance at 405 nm assuming a molar extinction coe¤-
cient E
405
=18 000 M
31
cm
31
[6]. Michaelis-Menten constants were
calculated using the non-linear regression program ENZFITTER [26].
The e¡ect of pH on the PTPase activity of the recombinant forms
of CD45 was studied using 10 mM p-NPP as substrate under similar
conditions as above. Bu¡ers used for these tests were as follows: pH
4^5.25, 100 mM acetate; pH 5.5^6.25, 100 mM citrate; pH 6.5^7.25,
100 mM imidazol; pH 7.5^8.5, 100 mM Tris-HCl. All bu¡ers con-
tained 1 mM EDTA, 0.1% 2-ME and 50 mM NaCl. pH dependence
data were ¢tted by non-linear least-squares regression using the pro-
gram KaleidaGraph 3.0.
3. Results and discussion
The cytoplasmic region of CD45 (PTP-I+II) as well as each
separate PTP domain (PTP-I and PTP-II) (Fig. 1) were ex-
pressed as MBP fusion proteins in bacteria under control of
the maltose promoter, and puri¢ed to near homogeneity (Fig.
2). Each construction was tested for PTPase activity using p-
NPP as a substrate. Recombinant proteins containing the en-
tire cytoplasmic region of CD45 (MBP^PTP-I+II and PTP-
I+II) displayed a phosphatase activity (Table 1) comparable
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Fig. 1. Di¡erent constructions of human CD45. MBP: maltose-binding protein. Numbering of residues as in Streuli et al. (1987)[22].
Fig. 2. SDS-PAGE analysis of MBP^CD45 constructions. A: MBP^PTP-I+II; B: MBP^PTP-I; C: MBP^PTP-II. Lane 1: after amylose a¤nity
chromatography. Lane 2: after factor Xa treatment. Lane 3: after anion exchange chromatography.
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to similar constructions studied by other authors [6,27,28].
Also, as expected, no enzymatic activity was detected in the
recombinant proteins lacking the ¢rst phosphatase domain
(MBP^PTP-II and PTP-II). However, MBP^PTP-I was found
to be an active phosphatase, in contrast with previous work
that reported the lack of catalytic activity of PTP-I in the
absence of the second domain [12,13]. Both MBP^PTP-I
and MBP^PTP-I+II displayed K
m
values in the mM range,
which are similar to the values reported by other authors for
CD45 and other PTPases [6,27,28]. As shown in Table 1, V
max
and k
cat
/K
m
values of MBP^PTP-I and MBP^PTP-II di¡er in
about one order of magnitude, indicating that the absence of
the second domain in£uences, but does not abrogate, the
phosphatase activity of the ¢rst PTP domain. Similar results
were obtained when two pY-peptides from hirudin and gastrin
(Tyrosine Phosphatase Assay Kit, Boehringer) were used as
substrates (data not shown).
Functional studies of di¡erent CD45 constructions sug-
gested that speci¢c interactions with the second domain are
necessary to have a ¢rst active domain [13,20,21]. In a similar
way, the phosphatase activity of MBP^PTP-I protein (in the
absence of the second domain) might be accounted for either
by speci¢c interactions of PTP-I with MBP or by protein
dimerization as observed, for example, in receptor-associated
protein tyrosine kinases [29,30]. In order to test whether the
covalently linked MBP was involved in PTP-I activation,
MBP^PTP-I was treated with Factor Xa to separate the fu-
sion partners. This experiment revealed a progressive loss of
PTPase activity following the addition of Factor Xa (Fig. 3),
indicating that the ¢rst PTP domain alone was not an active
phosphatase. On the other hand, cleavage of the MBP moiety
from the fusion protein containing the entire cytoplasmic re-
gion did not signi¢cantly a¡ect the PTPase activity.
The possibility that the enzymatic activity of MBP^PTP-I
activation could arise from protein dimerization was also in-
vestigated, since previous experimental evidences indicated
that CD45 could be regulated by dimerization. For example,
using cross-linking reagents in YAC-1 cell lysates, Takeda et
al. detected CD45 homodimers apparently induced by a
CD45-associated protein [31]. Furthermore, epidermal growth
factor (EGF)-induced dimerization of an arti¢cial EGF/CD45
chimera expressed in CD45-de¢cient T-cell line caused the loss
of antigen-dependent activation [32]. Using gel ¢ltration chro-
matography at di¡erent MBP^PTP-I concentrations, we ob-
served monomers, dimers and higher oligomers of MBP^PTP-
I. However, we have only found PTPase activity in fractions
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Fig. 4. The phosphatase activity is associated with the monomeric form of MBP^PTP-I after denaturation/renaturation. Aggregated (inactive)
MBP^PTP-I was treated with 2.5% SDS and 5 M Urea and renatured by gel ¢ltration (Superdex 200 SMART0). The fractions corresponding
to the monomer, dimer and higher oligomeric forms were incubated with p-NPP (10 mM ¢nal) at 37³C for 12 h. The apparent PTP activity is
represented by bars.
Fig. 3. Progressive loss of PTPase activity of MBP^PTP-I after
treatment with factor Xa. MBP^PTP-I (E) and MBP^PTP-I+II (8)
were incubated with factor Xa at di¡erent times and their respective
PTPase activities determined afterwards. pNPP (10 mM ¢nal) was
used as substrate. Each point represents the mean value of quadru-
plicated experiences and was calculated as the percentage of dephos-
phorylation of pNPP exhibited. 100% of activity was considered as
the activity displayed in identical conditions of incubation but in
the absence of factor Xa.
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corresponding to the monomeric form, even after denatura-
tion/renaturation of MBP^PTP-I (Fig. 4). These observations
are consistent with the crystallographic study of RPTPK,
which demonstrated that homodimerization of the ¢rst PTP
domain inactivated the enzyme by blocking the access of sub-
strate to the catalytic site [33].
At this point, our results demonstrated that: (i) the N-ter-
minal PTP domain of CD45 can be an active phosphatase in
the absence of the second domain, (ii) the PTP activity is only
evidenced when PTP-I covalently bound to MBP (or to PTP-
II in the wild-type enzyme) and (iii) the monomeric form of
MBP^PTP-I is responsible for the phosphatase activity. In the
light of these results, we may speculate that MBP activates the
¢rst PTP domain of CD45 through speci¢c protein^protein
interactions. This interaction probably involves contact resi-
dues close to the active site cleft and could compensate, at
least partially, the putative contacts induced in wild-type
CD45 by the presence of the second PTP domain. A structural
model of the MBP^PTP-I protein provides additional support
to this hypothesis. In the fusion protein, the C-terminal region
of MBP is connected through a 22 amino acid-long linker to
the N-terminal segment of PTP-I, a region which folds into an
K-helix close to the substrate-binding cleft in monomeric
phosphatases (Fig. 5). In particular, two loops of the PTP
domains close to the N-terminal K-helix contain important
functional residues. One of these loops has two glutamine
residues (corresponding to Gln
872
and Gln
876
in CD45^PTP-
I) which are highly conserved in the family of protein tyrosine
FEBS 18851 12-9-97
Table 1
Kinetic constants for dephosphorylation of p-NPP by di¡erent CD45 constructions
K
m
V
max
k
cat
/K
m
³C
(mM) (Wmol/min) (s
31
M
31
)
MBP^PTP-I
a
0.8 þ 0.2 22.98þ2.1 1 233 37
MBP^PTP-I+II 1.75þ 0.24 348.6 þ1.2 12 297 37
PTP-I+II
b
4.8 36 11 000 25
a
Values were corrected assuming that only the monomeric form of MBP^PTP-I was an active PTPase.
b
Values taken from Cho et al. (1993)[27].
Fig. 5. Ribbon model of the active site of monomeric phosphatases. The nucleophilic cysteine residue is labelled. In our construction, the MBP
moiety is fused to the NH
2
terminus of the PTP domain (indicated with an arrow) and could therefore interact with neighbouring PTP loops
(shown in darker colour) containing functionally critical residues (Asp, Gln). The ¢gure was drawn with MOLSCRIPT [36].
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phosphatases and which have been proposed to be involved in
substrate binding interactions [4,5]. A second loop close to the
N-terminal K-helix of monomeric phosphatases contains the
putative proton donor (Asp
796
in CD45) and undergoes a
signi¢cant conformational change upon the binding of phos-
photyrosine to the active cleft (reviewed in [7]). Given their
proximity to the N-terminal K-helix (and therefore to MBP),
these loops might be involved in interdomain contacts, that
could account for PTP-I activation.
Modi¢cations of the local structural environment close to,
or within, the active site cleft might a¡ect the pKa value of
functionally critical residues. The study of the pH dependence
of the enzymatic activity could therefore provide an indirect
evidence about MBP-contact regions in the neighbourhood of
the PTP-I active site. As expected, the two constructions con-
taining the entire cytoplasmic region (MBP^PTP-I+II and
PTP-I+II) displayed similar bell-shaped pro¢les with a max-
imum at pH 5^5.2 (Fig. 6). These values are within the pKa
ranges observed for other PTPases [6] and con¢rm our pre-
vious results (Fig. 3) showing that the presence of MBP did
not a¡ect the catalytic properties of PTP-I+II. However, the
absence of the second PTP domain caused a displacement of
the activity curve towards higher pH values, with an optimal
activity at 5.8^6.2 for the MBP/PTP-I protein. These di¡er-
ences are apparently due to a change in the ascending slope of
the activity curve and suggest that a region near the active site
of the PTP-I domain might directly interact with the MBP
moiety in the fusion protein. In the case of wild-type CD45,
similar interactions between the two PTP domains could serve
to regulate the PTPase activity [13,20,21], although other
mechanisms of regulation, such as phosphorylation and exter-
nal ligand binding have also been proposed [34,35]. Ultimate
validation of this hypothesis can only be provided by further
biochemical and structural studies of CD45 and other mem-
bers of the RPTP family.
In conclusion, our results demonstrate that the ¢rst PTP
domain of CD45 may be an active phosphatase in the absence
of the second domain. However, a functional PTP-I domain
requires speci¢c protein^protein interactions with an addition-
al factor (MBP or PTP-II), a particular feature of CD45 that
may di¡erentiate it from other receptor-like transmembrane
phosphatases.
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Fig. 6. Dephosphorylation of pNPP for the di¡erent active forms of
CD45 as a function of pH. The solid line and (E) represents MBP^
PTP-I, the dashed line and (X) represents PTP-I+II, and the dot
line and (8) represents MBP^PTP-I+II.
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